Skip to main content
Advertisement
Advertisement
ABOS
ABOS logo
Acumen Pharmaceuticals, Inc. Common Stock
0.21
USD
Sponsored
0.00
-1.83%
Nov 13, 15:59 UTC -5
Closed
exchange

After-Market

0.20

-0.01
-4.21%

Acumen Pharmaceuticals, Inc. Common Stock (ABOS) Earnings

ABOS Earnings Reports

Positive Surprise Ratio

ABOS beat 10 of 22 last estimates.

45%

Next Report

Date of Next Report
Mar 24, 2027
Estimate for Q4 26 (Revenue/ EPS)
--
/
-$0.38
Implied change from Q3 26 (Revenue/ EPS)
--
/
+8.57%
Implied change from Q4 25 (Revenue/ EPS)
--
/
-7.32%

Acumen Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On Oct 26, 2026, ABOS reported earnings of -0.35 USD per share (EPS) for Q3 26, beating the estimate of -0.39 USD, resulting in a 11.79% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +14.65% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -0.38 USD, with revenue projected to reach -- USD, implying an increase of 8.57% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Pelthos Therapeutics Inc.
Report Date
Nov 12, 2026 For Q3 26
Estimate
-$2.20
Actual
-$3.09
Surprise
-39.99%
logo
Biofrontera Inc. Common Stock
Report Date
Nov 13, 2026 For Q3 26
Estimate
-$0.11
Actual
-$0.42
Surprise
-274.33%
logo
Actuate Therapeutics, Inc. Common stock
Report Date
Nov 13, 2026 For Q3 26
Estimate
-$0.17
Actual
-$0.14
Surprise
+19.26%
logo
Acurx Pharmaceuticals, Inc. Common Stock
Report Date
Nov 12, 2026 For Q3 26
Estimate
-$0.38
Actual
-$0.49
Surprise
-27.54%
logo
Parabilis Medicines, Inc. Common Stock
Report Date
Nov 12, 2026 For Q3 26
Estimate
-$0.40
Actual
-$0.36
Surprise
+10.27%
logo
Avalyn Pharma Inc. Common Stock
Report Date
Nov 12, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.67
Surprise
+7.92%
logo
Inhibrx Biosciences, Inc. Common Stock
Report Date
Nov 13, 2026 For Q3 26
Estimate
-$2.57
Actual
-$2.46
Surprise
+4.41%
logo
Sagimet Biosciences Inc. Series A Common Stock
Report Date
Nov 12, 2026 For Q3 26
Estimate
-$0.26
Actual
-$0.31
Surprise
-17.03%
logo
Monopar Therapeutics Inc. Common Stock
Report Date
Nov 12, 2026 For Q3 26
Estimate
-$0.88
Actual
-$0.72
Surprise
+18.81%
logo
TuHURA Biosciences, Inc. Common Stock
Report Date
Nov 13, 2026 For Q3 26
Estimate
-$0.14
Actual
-$0.10
Surprise
+28.72%
FAQ
For Q3 2026, Acumen Pharmaceuticals, Inc. Common Stock reported EPS of -$0.35, beating estimates by 11.79%, and revenue of $0.00, 0% as expectations.
The stock price moved up 14.65%, changed from $1.98 before the earnings release to $2.27 the day after.
The next earning report is scheduled for Mar 24, 2027.
Based on -- analysts, Acumen Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.38 and revenue of -- for Q4 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement